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Introduction
Despite a signiﬁ  cant increase in our understanding of the 
pathogenesis of Alzheimer’s disease (AD) over the past 
two decades, the therapeutic options are still very 
modest. Cholinesterase inhibitors and the N-methyl-d-
aspartate receptor agonists currently available have a 
modest clinical eﬀ   ect but do not intervene with the 
underlying pathophysiology [1]. Th   e ultimate aim of AD 
therapy is to stop or slow down the underlying disease 
process.
Recently the ﬁ  rst two large trials with drugs that may 
slow disease progression have been published: a phase 2, 
passive immunization trial with bapineuzumab; and a 
phase 3 trial with tarenﬂ  urbil, a modulator of γ-secretase. 
Both drugs supposedly interfere with β-amyloid (Aβ) 
metabolism. Abnormalities in Aβ processing are thought 
to be central in AD pathophysiology according to the 
amyloid cascade hypothesis. Th  e mode of action of 
bapineuzumab is to remove aggregated Aβ, while 
tarenﬂ  urbil decreases the production of the pathogenic 
Aβ42 peptide. In the present commentary, we discuss the 
results of these trials and the implications for future 
therapy and insight into AD pathophysiology.
The amyloid cascade
Th  e amyloid hypothesis has led to an understanding of 
the pathology of AD, and also provides a basis for novel 
drug development. Th   is hypothesis suggests that 
increased Aβ42 production and subsequent aggregation 
in limbic and association cortices leads to synaptic 
changes and causes deposition of Aβ42 in diﬀ  use plaques, 
which in turn causes microglial and astrocytic activation. 
As a result, altered neuronal homeostasis and oxidative 
injury lead to tangle formation, and eventually to 
neuronal and synaptic dysfunction and selective neuronal 
loss [2,3]. Th   e most important implied prediction of the 
hypothesis is that reduction of Aβ aggregation would 
ameliorate AD symptoms.
Th   ree methods for intervening in the amyloid cascade 
have thus far been tested in clinical trials: active immuni-
zation, passive immunization, and modulation of γ-
secretase [4,5]. In this light we shall discuss the two 
recent clinical trials mentioned above: the phase 2 trial 
with bapineuzumab, and the phase 3 trial with 
taren ﬂ  urbil.
Bapineuzumab
Bapineuzumab is a humanized anti-Aβ monoclonal anti-
body. Preclinical passive immunotherapy studies with 
monoclonal anti-Aβ antibodies in a mouse model of AD 
showed antibody binding to Aβ plaques, reduction in Aβ 
plaque burden, and reversal of memory defects [6,7]. 
Bapineuzumab is directed against the N-terminus of Aβ 
and is hypothesized to bind to Aβ in the brain and to 
facilitate its removal.
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Alzheimer’s disease.
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trial in mild to moderate AD tested the safety and eﬃ   cacy 
of bapineuzumab [8]. Two hundred and thirty-four AD 
patients were randomly assigned to intravenous bapineu-
zu mab  (n  = 124) or to placebo (n  = 110) in four dose 
cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received six 
infusions, 13 weeks apart, with ﬁ   nal assessments 18 
months later. Th  e primary eﬃ   cacy  analysis  compared 
treatment diﬀ   erences within dose cohorts on the 
Alzheimer’s Disease Assessment Scale for Cognition and 
on the Disability Assessment for Dementia. No signiﬁ  cant 
diﬀ  erences were found in the primary eﬃ   cacy analysis.
Exploratory analyses, however, showed potential 
treatment diﬀ  erences on cognitive and functional end-
points in study completers and apolipoprotein E (APOE) 
ε4 noncarriers. In this subgroup, subjects on active treat-
ment showed 5 points less decline on the Alzheimer’s 
Disease Assessment Scale for Cognition after 78 weeks 
compared with placebo. A safety concern was the 
occurrence of reversible vasogenic edema, detected on 
brain magnetic resonance imaging in 10% of the 
bapineuzumab-treated patients. Vasogenic edema was 
more frequent in APOE ε4 carriers, which may suggest 
that vasogenic edema is related to vascular amyloid 
burden since APOE ε4 carriers show more vascular 
amyloid deposition.
Th   e potential treatment diﬀ  erences in the exploratory 
analyses have led to the evaluation of bapineuzumab in a 
phase 3 trial that started in December 2007, which will 
take possible treatment diﬀ  erences by APOE ε4 status 
into consideration. Meanwhile, a recent publication 
showed that treatment with bapineuzumab for 78 weeks 
reduced ﬁ   brillar amyloid burden in subjects with AD, 
shown by Pittsburgh compound B positron emission 
tomography ((PiB-PET) [9].
Tarenfl  urbil
Tarenﬂ  urbil is a modulator of the activity of γ-secretase, 
and may for that reason act as an Aβ42 lowering agent. In 
mouse models of AD, tarenﬂ  urbil prevents learning and 
memory deﬁ  cits and reduces Aβ42 brain concentrations 
[10]. In an earlier phase 2 trial in 210 AD patients, mildly 
aﬀ  ected patients (baseline mini-mental state examination 
20 to 26), who received 800 mg tarenﬂ  urbil twice per day, 
had lower rates of decline in activities of daily living and 
global function compared with subjects who received 
placebo [11].
Th  ese results led to a large multicentre, phase 3, 
randomized, double-blind, placebo-controlled trial for 
the evaluation of the eﬃ   cacy, safety, and tolerability of 
tarenﬂ  urbil in 1,684 subjects with mild AD (mini-mental 
state examination 15 to 26) [12]. Initially, patients were 
assigned to treatment with tarenﬂ  urbil at doses of either 
400 or 800 mg twice daily or placebo. After an analysis of 
phase 2 data indicated that subjects had the strongest 
response to 800 mg tarenﬂ  urbil twice daily, however, the 
400  mg dose was ended. Th  e main outcome measures 
were the change from baseline to 18 months score on the 
Alzheimer’s Disease Assessment Scale for Cognition and 
on the Alzheimer’s Disease Cooperative Study – 
Activities of Daily Living scale. Tarenﬂ   urbil had no 
beneﬁ  cial eﬀ  ect on the primary or secondary outcomes. 
Th   e APOE genotype had no eﬀ  ect on treatment response. 
Th  e  tarenﬂ  urbil group had a small increase in frequency 
of dizziness, anemia, and infections.
Discussion
What have these two trials taught us? Th  e  bapineuzumab 
trial showed that intravenous administration of the serial 
bapineuzumab doses is feasible and, as long as the 
possible occurrence of vasogenic edema is monitored, is 
relatively safe. Th   e positron emission tomography 
substudy provided the suggestion that bapineu  zu  mab 
indeed reduces amyloid load in vivo. Th   e lack of eﬀ  ect on 
the primary endpoint of the trial may be due to the fact 
that, as the authors point out, it was underpowered to 
show small diﬀ  erences in eﬃ   cacy. Indeed, a larger sample 
size would have increased the ability to detect statistically 
signiﬁ  cant diﬀ  erences, but this does not alter the notion 
that clinical eﬀ   ects may still be small and of limited 
relevance. In the case of the tarenﬂ  urbil trial, it is possible 
that the dose of 800 mg twice daily was still too low. Th  e 
discrepant ﬁ   ndings between the phase 2 subgroup 
analyses and the phase 3 study strongly caution against 
apparent  overinter pre tation  of  post hoc analyses.
Th  e  ﬁ  ndings may also have implications for the amyloid 
hypothesis. First, it is possible that the relation between 
amyloid processing and AD is modiﬁ  ed by the APOE 
genotype, and in this respect it will be interesting to see 
how a possible treatment eﬀ  ect may diﬀ  er by APOE ε4 
status in the new phase 3 bapineuzumab study. It stresses 
again how important APOE is in several aspects of AD 
[13,14].
Second, as reduction of Aβ42 was not eﬀ  ective and 
removal of aggregated Aβ had a limited eﬀ  ect, other Aβ 
species may be the main toxic agent in AD or the AD 
pathology may not depend on Aβ. Alternative models for 
AD pathophysiology may better explain how accumu-
lation of Aβ42 leads to tangle formation, and why tangle 
formation is closer to neuronal cell death than amyloid 
accumulation [2].
Th  ird, reduction of Aβ production or removal of Aβ 
may not be successful in patients who already have a 
substantial amyloid burden if the cascade becomes 
independent of amyloid burden once Aβ42 accumulation 
has set oﬀ   an irreversible chain of events.
Finally, the amyloid hypothesis neglects the role of 
cerebrovascular damage, which is typically comorbid in 
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causing neurodegeneration and may interact with the 
pathology of AD [15]. Cerebrovascular damage is a factor 
that may have to be taken into account when developing 
new therapeutic strategies for AD.
Abbreviations
Aβ, β-amyloid; AD, Alzheimer’s disease; APOE, apolipoprotein E.
Competing interests
NDP has a senior fellowship at the Alzheimer Center VUmc partly supported 
by Vereniging AEGON. PJV is the recipient of a grant award from Bristol-Myers 
Squibb and is a consultant to Elan, Wyeth, Bristol-Myers Squibb, Myriad 
Pharmaceuticals and Danone Research. PS has consulted for Elan-Wyeth, 
Bristol-Myers Squibb, Myriad Pharmaceuticals, and Danone Research.
Acknowledgements
The study was in part funded by the European Commission within the sixth 
framework programme (LSHB-2007-037670, to PJV).
Author details
1Alzheimer Center, VU University Medical Center, Boelelaan 1118, 
Amsterdam, The Netherlands. 2Alzheimer Centre, School for Mental Health 
and Neuroscience, Maastricht University Medical Centre, Maastricht, The 
Netherlands.
Published: 9 April 2010
References
1.  Scarpini E, Scheltens P, Feldman H: Treatment of Alzheimer’s disease: 
current status and new perspectives. Lancet Neurol 2003, 2:539-547.
2. Hardy  J:  The amyloid hypothesis for Alzheimer’s disease: a critical 
reappraisal. J Neurochem 2009, 110:1129-1134.
3. Selkoe  DJ:  Alzheimer disease: mechanistic understanding predicts novel 
therapies. Ann Intern Med 2004, 140:627-638.
4.  Gilman S, Koller M, Black RS, Jenkins L, Griffi   th SG, Fox NC, Eisner L, Kirby L, 
Rovira MB, Forette F, Orgogozo JM: Clinical eff  ects of Aβ immunization 
(AN1792) in patients with AD in an interrupted trial. Neurology 2005, 
64:1553-1562.
5.  Schenk D, Games D, Seubert P: Potential treatment opportunities for 
Alzheimer’s disease through inhibition of secretases and Aβ 
immunization. J Mol Neurosci 2001, 17:259-267.
6.  Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, 
Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, 
Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, 
Schenk D, Yednock T: Peripherally administered antibodies against amyloid 
beta-peptide enter the central nervous system and reduce pathology in a 
mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
7.  Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong 
CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory 
defi  cits without reducing brain Aβ burden in Alzheimer’s disease model. 
Nat Neurosci 2002, 5:452-457.
8.  Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, 
Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, 
Lieberburg I, Schenk D, Black R, Grundman M: A phase 2 multiple ascending 
dose trial of bapineuzumab in mild to moderate Alzheimer disease. 
Neurology 2009, 73:2061-2070.
9.  Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, 
Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller 
M, Gregg KM, Schenk D, Black R, Grundman M: 11C-PiB PET assessment of 
change in fi  brillar amyloid-beta load in patients with Alzheimer’s disease 
treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, 
ascending-dose study. Lancet Neurol 2010, 9:363-372.
10.  Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, 
Nicolle MM: Chronic administration of R-fl  urbiprofen attenuates learning 
impairments in transgenic amyloid precursor protein mice. BMC Neurosci 
2007, 8:54.
11.  Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA: Effi   cacy 
and safety of tarenfl  urbil in mild to moderate Alzheimer’s disease: a 
randomised phase II trial. Lancet Neurol 2008, 7:483-493.
12.  Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz 
KH: Eff  ect of tarenfl  urbil on cognitive decline and activities of daily living 
in patients with mild Alzheimer disease: a randomized controlled trial. 
JAMA 2009, 302:2557-2564.
13.  Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der 
Flier WM: CSF biomarkers in Alzheimer’s disease and controls: associations 
with APOE genotype are modifi  ed by age. J Alzheimers Dis 2009, 
16:601-617.
14.  Van der Flier WM, Schoonenboom SNM, Pijnenburg YAL, Fox NC, Scheltens P: 
The eff  ect of APOE genotype on clinical phenotype in Alzheimer’s disease. 
Neurology 2006, 67:526-527.
15.  De Leeuw F-E, Korf E, Barkhof F, Scheltens P: White matter lesions are 
associated with progression of medial temporal lobe atrophy in Alzheimer 
disease. Stroke 2006, 37:2248-2252.
doi:10.1186/alzrt28
Cite this article as: Prins ND, et al.: Can novel therapeutics halt the amyloid 
cascade? Alzheimer’s Research & Therapy 2010, 2:5.
Prins et al. Alzheimer’s Research & Therapy 2010, 2:28 
http://alzres.com/content/2/2/5
Page 3 of 3